A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.

Paolo Ragonese, Katrin Plewnia, Mariarosa Rottoli, Davide Maimone, Maura Frigo, Paolo Confalonieri, Enrico Montanari, Nunzia Alessandra Losignore, Antonella Veneziano, Antonello Pala, Ada Francia

Risultato della ricerca: Article

1 Citazione (Scopus)

Abstract

INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS). RESULTS: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.
Lingua originaleEnglish
pagine (da-a)105-109
Numero di pagine5
RivistaJournal of the Neurological Sciences
Volume364
Stato di pubblicazionePublished - 2016

Fingerprint

Multiple Sclerosis
Observational Studies
Prospective Studies
Depression
Anxiety
Therapeutics
Health Surveys
Health Personnel
Italy
Emotions

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cita questo

A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. / Ragonese, Paolo; Plewnia, Katrin; Rottoli, Mariarosa; Maimone, Davide; Frigo, Maura; Confalonieri, Paolo; Montanari, Enrico; Losignore, Nunzia Alessandra; Veneziano, Antonella; Pala, Antonello; Francia, Ada.

In: Journal of the Neurological Sciences, Vol. 364, 2016, pag. 105-109.

Risultato della ricerca: Article

Ragonese, P, Plewnia, K, Rottoli, M, Maimone, D, Frigo, M, Confalonieri, P, Montanari, E, Losignore, NA, Veneziano, A, Pala, A & Francia, A 2016, 'A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.', Journal of the Neurological Sciences, vol. 364, pagg. 105-109.
Ragonese, Paolo ; Plewnia, Katrin ; Rottoli, Mariarosa ; Maimone, Davide ; Frigo, Maura ; Confalonieri, Paolo ; Montanari, Enrico ; Losignore, Nunzia Alessandra ; Veneziano, Antonella ; Pala, Antonello ; Francia, Ada. / A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. In: Journal of the Neurological Sciences. 2016 ; Vol. 364. pagg. 105-109.
@article{3a3be419123343a293f3fbec8790feef,
title = "A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.",
abstract = "INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS). RESULTS: Of 250 enrolled patients, 222 (88.8{\%}) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.",
keywords = "Anxiety; Depression; Disease-modifying treatment; Emotional burden; Multiple sclerosis; Adolescent; Adult; Aged; Female; Humans; Immunologic Factors; Italy; Logistic Models; Male; Middle Aged; Mood Disorders; Multiple Sclerosis; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Young Adult; Treatment Outcome; Neurology; Neurology (clinical)",
author = "Paolo Ragonese and Katrin Plewnia and Mariarosa Rottoli and Davide Maimone and Maura Frigo and Paolo Confalonieri and Enrico Montanari and Losignore, {Nunzia Alessandra} and Antonella Veneziano and Antonello Pala and Ada Francia",
year = "2016",
language = "English",
volume = "364",
pages = "105--109",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.

AU - Ragonese, Paolo

AU - Plewnia, Katrin

AU - Rottoli, Mariarosa

AU - Maimone, Davide

AU - Frigo, Maura

AU - Confalonieri, Paolo

AU - Montanari, Enrico

AU - Losignore, Nunzia Alessandra

AU - Veneziano, Antonella

AU - Pala, Antonello

AU - Francia, Ada

PY - 2016

Y1 - 2016

N2 - INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS). RESULTS: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.

AB - INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS). RESULTS: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.

KW - Anxiety; Depression; Disease-modifying treatment; Emotional burden; Multiple sclerosis; Adolescent; Adult; Aged; Female; Humans; Immunologic Factors; Italy; Logistic Models; Male; Middle Aged; Mood Disorders; Multiple Sclerosis; Prospective Studies; Psych

UR - http://hdl.handle.net/10447/181236

UR - http://www.elsevier.com/locate/jns

M3 - Article

VL - 364

SP - 105

EP - 109

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -